Press Releases Medivir AB

Stocks

MVIR B

SE0020181014

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 20:00:00 11/06/2026 +04			5-day change	1st Jan Change
1.720 ^SEK	+0.82%		-0.58%	+320.54%

06-09	Medivir's fostrox study published in leading cancer journal	FW
06-01	Certain Ordinary Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 1-JUN-2026.	CI

Press Releases

05-05	Medivir : INTERIM REPORT JANUARY – MARCH 2026	PU
04-08	Medivir : Notice of Annual General Meeting of Medivir AB (publ)	PU
03-10	Medivir : Presentation	PU
03-10	Medivir : Presentation	PU
03-05	Medivir : Presentation	PU
02-18	Medivir : Presentation	PU
02-18	Medivir : Year-End Report, January - December 2025	PU
02-09	Medivir : announces the outcome of the directed share issue which was announced on 5 February 2026	PU
02-05	Medivir : carries out a directed share issue of SEK 45 million to Carl Bennet AB	PU
02-03	Medivir : Presentation	PU
12-02	Medivir : presenting at the Redeye Life Science Day 2025	PU
12-01	Medivir : Presentation	PU
11-28	Medivir : partner Vetbiolix announces publication of Landmark Proof-of-Concept Clinical Study Results for VBX-1000 (MIV-701)	PU
11-27	Medivir : FDA grants Medivir´s MIV-711 Orphan Drug Designation for the treatment of Osteogenesis Imperfecta	PU
11-26	Medivir : presenting at the Aktiespararnas Stora Aktiedagar	PU
11-25	Medivir : Presentation	PU
11-24	Medivir : presenting at the DNB Carnegie Nordic Healthcare conference	PU
11-18	Medivir : live Investor Update today at Redeye at 11.00	PU
11-14	Medivir : publishes disclosure document regarding rights issue	PU
11-10	Medivir : BULLETIN FROM EXTRAORDINARY GENERAL MEETING in MEDIVIR AB (PUBL)	PU
11-06	Medivir : Presentation	PU
11-06	Medivir : Interim Report, January - September 2025	PU
11-06	MEDIVIR : INTERIM REPORT JANUARY - SEPTEMBER 2025	PU
29/10/25	Medivir : postpones the appointment of a new Nomination Committee	PU
23/10/25	Medivir : enters exclusive licensing agreement with Biossil, Inc. for remetinostat	PU